Drug Profile
Retagliptin - Jiangsu HengRui Medicine
Alternative Names: Retagliptin phosphate tablets; SP 2086Latest Information Update: 20 Sep 2023
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics; Carboxylic acids; Fluorobenzenes; Imidazoles; Pyrazines; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Type 2 diabetes mellitus
Most Recent Events
- 20 Sep 2023 Jiangsu HengRui Medicine plans a phase I trial for Diabetes mellitus (PO) in September 2023 (NCT06035406)
- 26 Jun 2022 Retagliptin is still in preregistration stage for Type-2 diabetes mellitus (Motherapy) in China (PO) (Jiangsu Hengrui Pharmaceuticals pipeline, June 2022)
- 26 Jun 2022 Retagliptin is still in preregistration stage for Type-2 diabetes mellitus (Combination therapy) in China (PO) (Jiangsu Hengrui Pharmaceuticals pipeline, June 2022)